ROS1 Biomarkers
News and reporting on ROS1 biomarkers.
Innovent's Dovbleron Gains Approval in China for ROS1-Positive NSCLC
The firm also out-licensed its DLL3 antibody-drug conjugate candidate, IBI3009, to Roche this week.
Nuvation Bio Seeking FDA Approval for Taletrectinib in ROS1-Positive NSCLC
The agency has granted the firm's NDA priority review and is expected to issue a decision by June 23, 2025.
Avistone Biotechnology to Begin Trial of Next-Generation ROS1/NTRK Inhibitor
The firm will study ANS03 in patients with tumors harboring a ROS1 or NTRK alteration, including those with acquired resistance mutations.
CHMP Recommends BMS's Augtyro for ROS1-Positive NSCLC, NTRK-Positive Tumors
The European Commission will decide whether to approve Augtyro in these two indications in January 2025.
In the TRUST-II trial, 85 percent of ROS1 TKI-naïve NSCLC patients and 62 percent of TKI-pretreated patients responded to the next-generation ROS1 inhibitor.